Go to
current issue
-
FDA approves first chikungunya vaccine Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-12-04
Discover the world’s best science and medicine | Nature.com
-
PROTAC in clinic for autoimmune skin disease Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-12-04
Discover the world’s best science and medicine | Nature.com
-
Gene therapy zeroes in on Parkinson disease brain circuits Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-12-04
Discover the world’s best science and medicine | Nature.com
-
FDA approves first-in-class AKT inhibitor Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-12-04
Discover the world’s best science and medicine | Nature.com
-
A safer polyene antifungal Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-12-01
Discover the world’s best science and medicine | Nature.com
-
CAAR T cells to treat encephalitis Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-12-01
Discover the world’s best science and medicine | Nature.com
-
USP30 inhibition protects dopaminergic neurons Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-12-01
Discover the world’s best science and medicine | Nature.com
-
Open-science drug discovery for COVID-19 Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-12-01
Discover the world’s best science and medicine | Nature.com
-
Tailor made: the art of therapeutic mRNA design Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-11-29 Mihir Metkar, Christopher S. Pepin, Melissa J. Moore
-
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-11-29 Lieselotte Vande Walle, Mohamed Lamkanfi
-
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-11-29 Miriam Meyer, Andrea Mahr, Joanna Brewer, Volker Daniel, Justine Dell‘Aringa, Tony Goldstone, Sarah Hersey, Ian Johnston, Pamela Larson, Michael Loveridge, Gavin MacBeath, Mark Moyer, Dirk Nagorsen, Sophie Papa, Leanne Peiser, Koustubh Ranade, Ruben Rizzi, Axel Roers, Dolores Schendel, Pallavur Sivakumar, Eric Tran, Özlem Türeci, Luise Weigand, Anders Wennborg, Cassian Yee, Cedrik M. Britten
Current regulation of T cell receptor (TCR)-based therapeutics may require repeated testing of patients for specific HLA alleles as well as companion diagnostics development, despite the invariant nature of the HLA genotype and availability of robust clinical HLA tests. This increases the burden on patients and the organizations developing these products. We propose regulatory flexibility to facilitate
-
Targeting synapse function and loss for treatment of neurodegenerative diseases Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-11-27 Borislav Dejanovic, Morgan Sheng, Jesse E. Hanson
-
CRISPR gets the glory in landmark approval, but haemoglobin research made it possible Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-11-27
Stuart Orkin, of Harvard Medical School and HHMI, discusses how the discovery of BCL11A paved the way for Vertex and CRISPR Therapeutics’ exa-cel therapy for haemoglobinopathies.
-
Antibodies combat Gram-negative pathogen Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-11-22
Discover the world’s best science and medicine | Nature.com
-
The renal cell carcinoma drug market Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-11-21
Discover the world’s best science and medicine | Nature.com
-
The pipeline and market for migraine drugs Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-11-17
Discover the world’s best science and medicine | Nature.com
-
Biotechs step on cGAS for autoimmune diseases Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-11-10
Ventus has overcome medicinal chemistry challenges to advance a first inhibitor of cGAS-STING into the clinic, as drug developers build the case for novel anti-inflammatory agents in autoimmune diseases including lupus.
-
FDA new drug approvals in Q3 2023 Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-11-09
Discover the world’s best science and medicine | Nature.com
-
Trends in rare disease drug development Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-11-06
Discover the world’s best science and medicine | Nature.com
-
Immunology on the brain Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-11-08
Jane Grogan, Biogen’s new head of research, talks about immunology, rare diseases and her longstanding interest in the cancer target TIGIT.
-
A new shuttle for drug delivery across the blood–brain barrier Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-11-03
Discover the world’s best science and medicine | Nature.com
-
Bacteria tag tumours for CAR-T cell attack Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-11-03
Discover the world’s best science and medicine | Nature.com
-
Phosphatase inhibitor drives anticancer immune responses Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-11-01
Discover the world’s best science and medicine | Nature.com
-
PD1/PDL1 clinical trials adapt to a growing landscape of patients resistant to PDx Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-11-01
Discover the world’s best science and medicine | Nature.com
-
Octopus sucker mimic boosts drug absorption Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-31
Discover the world’s best science and medicine | Nature.com
-
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-31 Marco Ruella, Felix Korell, Patrizia Porazzi, Marcela V. Maus
-
Author Correction: Bridging the gap between innovation and later-stage financing for biotech in Europe. Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-11-01 Jing Gong,Jean-Loup Romet-Lemonne,Brandy Houser
-
Understanding long-lasting ketamine effects Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-31
Discover the world’s best science and medicine | Nature.com
-
Molecular glue-like STING activator Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-31
Discover the world’s best science and medicine | Nature.com
-
Targeting tumour-associated bacteria Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-31
Discover the world’s best science and medicine | Nature.com
-
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-27 Christopher A. Klebanoff, Smita S. Chandran, Brian M. Baker, Sergio A. Quezada, Antoni Ribas
-
Engineering a compact genome-editing tool Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-26
Discover the world’s best science and medicine | Nature.com
-
Drug developers back US$80 million African ancestry genomics initiative Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-25
Discover the world’s best science and medicine | Nature.com
-
FDA approves C5-blocking macrocyclic peptide for autoimmune disease Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-25
Discover the world’s best science and medicine | Nature.com
-
Glue-based KRAS inhibitors make their debut cancer trial mark Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-23
Discover the world’s best science and medicine | Nature.com
-
IRDiRC Drug Repurposing Guidebook: making better use of existing drugs to tackle rare diseases Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-23 Anneliene Hechtelt Jonker, Simon Day, Michela Gabaldo, Heather Stone, Martin de Kort, Daniel J. O’Connor, Anna Maria Gerdina Pasmooij
The International Rare Diseases Research Consortium (IRDiRC) has developed a new guidebook to invigorate drug repurposing for rare diseases.
-
Unrealized targets in the discovery of antibiotics for Gram-negative bacterial infections Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-13 Ursula Theuretzbacher, Benjamin Blasco, Maëlle Duffey, Laura J. V. Piddock
-
CAR T cell therapies raise hopes — and questions — for lupus and autoimmune disease Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-13
A pack of CAR T cell therapies are now in trials in systemic lupus erythematosus, as the race begins to prove the potential of autologous cell therapies in autoimmune diseases.
-
Neglected tropical diseases go global Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-13
The Drugs for Neglected Diseases initiative’s Delali Attipoe, Director of the non-profit’s North America branch, discusses the rising risks of climate-sensitive diseases such as dengue.
-
MDMA-assisted therapy for PTSD passes phase III trial Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-06
Discover the world’s best science and medicine | Nature.com
-
Genetic support for FDA-approved drugs over the past decade Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-06
Discover the world’s best science and medicine | Nature.com
-
FDA approves fourth JAK inhibitor for myelofibrosis Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-06
Discover the world’s best science and medicine | Nature.com
-
Novel schizophrenia therapy filed for FDA approval Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-06
Discover the world’s best science and medicine | Nature.com
-
Targeting expanded trinucleotide repeats Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-05
Discover the world’s best science and medicine | Nature.com
-
Reshaping the tumour microenvironment Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-05
Discover the world’s best science and medicine | Nature.com
-
Synthesizing portimines Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-05
Discover the world’s best science and medicine | Nature.com
-
Understanding GABAA receptor pharmacology Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-05
Discover the world’s best science and medicine | Nature.com
-
Stress can be exhausting for T cells Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-10-02
Discover the world’s best science and medicine | Nature.com
-
Microbial ‘dark matter’ yields new antibiotic Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-28
Discover the world’s best science and medicine | Nature.com
-
Rewired proteostasis in KRAS inhibitor resistance Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-27
Discover the world’s best science and medicine | Nature.com
-
Antipsychotic displays dual GPCR binding mode Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-26
Discover the world’s best science and medicine | Nature.com
-
Drug delivery systems for CRISPR-based genome editors Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-18 Victoria Madigan, Feng Zhang, James E. Dahlman
-
Angering both sides of the drug pricing aisle Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-14
ICER’s incoming President, Sarah Emond, discusses drug pricing, multimillion dollar gene therapies and innovation incentives.
-
Artificial intelligence for natural product drug discovery Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-11 Michael W. Mullowney, Katherine R. Duncan, Somayah S. Elsayed, Neha Garg, Justin J. J. van der Hooft, Nathaniel I. Martin, David Meijer, Barbara R. Terlouw, Friederike Biermann, Kai Blin, Janani Durairaj, Marina Gorostiola González, Eric J. N. Helfrich, Florian Huber, Stefan Leopold-Messer, Kohulan Rajan, Tristan de Rond, Jeffrey A. van Santen, Maria Sorokina, Marcy J. Balunas, Mehdi A. Beniddir, Doris
-
Macrocycle drugs serve up new opportunities Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-11
Merck & Co.’s PCSK9 inhibitor MK-0616 showcases the potential of macrocycles as oral drugs for extracellular targets, even as several companies explore intracellular and macrocycle–drug conjugate possibilities.
-
Upcoming market catalysts in Q4 2023 Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-08
Discover the world’s best science and medicine | Nature.com
-
Defining rare conditions in the era of personalized medicine Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-08 Daniel J. O’Connor, Michela Gabaldo, Annemieke Aartsma-Rus, Anneliene Hechtelt Jonker
The total number of rare conditions is debated, partly because of the variety of definitions of what constitutes rare. A broader consensus view of what rare means, based on improved understanding of individual group and patient clinicopathological characteristics, will help maximize the impact of technological advances in therapeutic development programmes.
-
FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-06
Discover the world’s best science and medicine | Nature.com
-
Obesity drug scores landmark cardiovascular win Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-06
Discover the world’s best science and medicine | Nature.com
-
A step closer to in vivo editing of haematopoietic stem cells Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-09-06
Discover the world’s best science and medicine | Nature.com
更新日期：2023-11-01
Copyright © 2014-2023 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495-2号
京公网安备 11010802027423号
京公网安备 11010802027423号